Trilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communications services to customers and international visitors roaming on its networks in the United States, Bolivia, and New Zealand. Its wireless voice and data communications services include local, international long distance, and roaming services. The Company also provides fixed broadband communications services to business and residential customers. It serves approximately 15.4 million customers. The company is headquartered in Bellevue, Washington.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-425-4585900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$791.59 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/27/2019 (Estimated)
OptionableNot Optionable
Trilogy International Partners (TSE:TRL) Frequently Asked Questions
What is Trilogy International Partners' stock symbol?
Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."
How often does Trilogy International Partners pay dividends? What is the dividend yield for Trilogy International Partners?
Trilogy International Partners declared a quarterly dividend on Friday, April 13th. Shareholders of record on Friday, May 4th will be given a dividend of 0.02 per share on Friday, May 4th. This represents a $0.08 dividend on an annualized basis and a yield of 3.76%. The ex-dividend date of this dividend is Friday, April 13th. View Trilogy International Partners' Dividend History.
When is Trilogy International Partners' next earnings date?
What price target have analysts set for TRL?
3 equities research analysts have issued 12-month target prices for Trilogy International Partners' stock. Their forecasts range from C$3.00 to C$8.00. On average, they expect Trilogy International Partners' share price to reach C$4.83 in the next year. This suggests a possible upside of 126.9% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.
What is the consensus analysts' recommendation for Trilogy International Partners?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.
Has Trilogy International Partners been receiving favorable news coverage?
News coverage about TRL stock has been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trilogy International Partners earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of Trilogy International Partners' key competitors?
Some companies that are related to Trilogy International Partners include Eco Animal Health Group (EAH), Medical Developments (MVP), BEXIMCO PHARMAC/S GDR REGS (BXP), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS), Avivagen (VIV), Futura Medical (FUM), Cathay International (CTI), NanoViricides (NNVC), Patrys (PAB), Sareum (SAR), Recce Pharmaceuticals (RCE), Antisense Therapeutics (ANP) and China Pharma (CPHI).
What other stocks do shareholders of Trilogy International Partners own?
Who are Trilogy International Partners' key executives?
Trilogy International Partners' management team includes the folowing people:
- Mr. John William Stanton, Co-Founder, Chairman & Lead Director (Age 64)
- Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 63)
- Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 66)
- Mr. Erik Mickels, Sr. VP & CFO
- Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.
How do I buy shares of Trilogy International Partners?
Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trilogy International Partners' stock price today?
One share of TRL stock can currently be purchased for approximately C$2.13.
How big of a company is Trilogy International Partners?
Trilogy International Partners has a market capitalization of C$118.57 million and generates C$791.59 million in revenue each year.
What is Trilogy International Partners' official website?
How can I contact Trilogy International Partners?
Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.
MarketBeat Community Rating for Trilogy International Partners (TSE TRL)
MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote "Outperform" if you believe TRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
